The historical rank and industry rank for D. Western Therapeutics Institute's Net Margin % or its related term are showing as below:
FRA:6DW'
s Net Margin % Range Over the Past 10 Years
Min: -615.48 Med: -156.99 Max: 22.95
Current: -368.47
FRA:6DW's Net Margin % is ranked worse than 67.8% of 938
companies
in the Biotechnology industry
Industry Median: -88.295
vs FRA:6DW: -368.47
D. Western Therapeutics Institute (FRA:6DW) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
D. Western Therapeutics Institute Net Margin % Related Terms
D. Western Therapeutics Institute Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute Net Margin % Chart
FRA:6DW vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, D. Western Therapeutics Institute's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Net Margin % distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute (FRA:6DW) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on D. Western Therapeutics Institute and its competitors. According to the industry distribution chart, D. Western Therapeutics Institute ranks #636 out of 938 companies in the Biotechnology industry, placing it in the top 67.8%.
Is D. Western Therapeutics Institute's Net Margin % too high?
D. Western Therapeutics Institute's current Net Margin % is 0.00%. Based on the distribution chart, D. Western Therapeutics Institute ranks #636 out of 938 companies in the Biotechnology industry, which is below the industry midpoint. Overall, D. Western Therapeutics Institute has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #636 out of 938 companies for Net Margin %. This places D. Western Therapeutics Institute in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (FRA:6DW) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.31, compared to a current price of €0.39 — trading 24.5% above its estimated fair value. The current Net Margin % is 0.00%. D. Western Therapeutics Institute's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For D. Western Therapeutics Institute (FRA:6DW), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (FRA:6DW) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of €0.39 is trading 24.5% above its estimated GF Value™ of €0.31.
GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.
Key valuation signals for FRA:6DW:
Net Margin %: 0.00%
GF Value™: €0.31 vs. price of €0.39 (24.5% above fair value)
No single metric tells the full story. See the FRA:6DW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Business Description
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
22GF Score
Get the complete analysis for FRA:6DW
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6DW has been successfully added to your 
